The present invention relates to formulations of nucleotide reversetranscriptase inhibitors (NRTIs), preferably [2-(6-Amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid (tenofovir, PMPA), or a physiologicallyfunctional derivative thereof, suitable for topical application and their usein the prevention of HIV infections.